The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders
Liver International · 2025
DOI: 10.1111/liv.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Meng Hsuan Kuo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan. Hauptthemen laut MEDLINE: Virus Activation, Rheumatic Diseases, Tumor Necrosis Factor-alpha, Hepatitis B virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Rheumatologic patients who test positive for hepatitis B surface antigen (HBsAg) or core antibody (HBcAb) are at risk of HBV reactivation when treated with TNF‐α inhibitors. The effect of TNF‐α inhibitor potency on this risk remains unclear, despite guidelines advising potency‐based risk stratification. This study examines how TNF‐α inhibitor potency influences the risk of HBV reactivation.
Methods
From January 2008 to June 2023, 711 new TNF‐α inhibitor users with rheumatic diseases were identified, including 39 HBsAg+ patients with antiviral prophylaxis, 72 HBsAg+ patients without antiviral prophylaxis, and 600 HBsAg−/HBcAb+ patients without prophylaxis. A Cox proportional hazards model assessed factors associated with HBV reactivation.
Results
Over 2526 person‐years of follow‐up, HBsAg+ patients without antiviral prophylaxis had the highest HBV reactivation rate at 104.1 per 1000 person‐years, followed by HBsAg−/HBcAb+ patients at 12.9, and HBsAg+ patients with antiviral prophylaxis at 12.6 per 1000 person‐years. Multivariate Cox regression revealed that high‐potency TNF‐α inhibitors significantly increased HBV reactivation risk in HBsAg+ patients without antiviral prophylaxis (aHR 3.24, 95% CI: 1.09–9.67, p = 0.04). Adalimumab had a higher reactivation risk compared to etanercept (aHR 3.23, 95% CI: 1.02–10.17, p = 0.04), followed by golimumab (aHR 3.27, 95% CI: 0.91–11.64, p = 0.07). For HBsAg−/HBcAb+ patients, TNF‐α inhibitor potency did not significantly impact HBV reactivation risk; instead, age over 65 was the only significant risk factor (aHR 3.37, 95% CI: 1.30–8.70, p = 0.01).
Conclusion
High‐potency TNF‐α inhibitors significantly increase HBV reactivation risk in HBsAg+ patients, while HBsAg−/HBcAb+ patients have a uniformly low risk across all inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.
- School of Medicine, Tzuchi University, Hualien, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.
- Division of Rheumatology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.
ORCID-Profile: Meng Hsuan Kuo, Chih-Wei Tseng, Kuo-Chih Tseng
Zitieren
APA
Kuo, M. H., Tseng, C. W., Tseng, K. C., Lu, M. C., Tung, C. H., Chen, N. T., Huang, K. Y., & Lai, N. S. (2025). The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders. Liver International. https://doi.org/10.1111/liv.70152
Vancouver
Kuo MH, Tseng CW, Tseng KC, Lu MC, Tung CH, Chen NT, et al. The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders. Liver International. 2025. doi:10.1111/liv.70152
BibTeX
@article{Kuo2025,
author = {Kuo, Meng Hsuan and Tseng, Chih-Wei and Tseng, Kuo-Chih and Lu, Ming-Chi and Tung, Chien-Hsueh and Chen, Nai-Tzu and Huang, Kuang-Yung and Lai, Ning-Sheng},
title = {The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70152}
}
EUVIMED